find the latest legal job
Corporate Counsel and Company Secretary
Category: Generalists - In House | Location: Newcastle, Maitland & Hunter NSW
· Highly-respected, innovative and entrepreneurial Not-for-Profit · Competency based Board
View details
Chief Counsel and Company Secretary
Category: Generalists - In House | Location: Newcastle, Maitland & Hunter NSW
· Dynamic, high growth organisation · ASX listed market leader
View details
In-house Projects Lawyer | Renewables / Solar | 2-5 Years PQE
Category: Generalists - In House | Location: All Australia
· Help design the future · NASDAQ Listed
View details
Insurance Lawyer (3-5 PAE)
Category: Insurance and Superannuation Law | Location: Brisbane CBD & Inner Suburbs Brisbane QLD
· Dynamic organisation ·
View details
Legal Counsel
Category: Corporate and Commercial Law | Location: North Sydney NSW 2060
· 18 month fixed term contract · 3-5 years PQE with TMT exposure
View details
Firm prepares for cancer patents hearing

Firm prepares for cancer patents hearing

A landmark legal action challenging the validity of breast and ovarian cancer gene patents will return to the Federal Court for a hearing next week.

 

Australian law firm Maurice Blackburn launched the legal action in June against four biotech companies to challenge a patent over human genetic material.

Maurice Blackburn united with the national consumer organisation Cancer Voices Australia and a Brisbane woman with breast cancer, arguing the biotech companies monopoly on cancer genes is unlawful.

In an Australian first, the case in the Federal Court will focus on the patent over a gene mutation known as BRCA1. The mutation is associated with an increased risk of breast and ovarian cancer in women.

Maurice Blackburn will argue that the patent held by companies including Myriad Genetics Inc and Melbourne-based Genetic Technologies Ltd (known as Patent 686,004) is invalid.

In March, the Federal District Court in New York ruled that patents were improperly granted to Myriad Genetics on two human genes, including BRCA1.

In Australia, the test case is supported by patent law expert Dr Luigi Palombi from Australian National University and Sydney University and will be run on a pro bono basis by Maurice Blackburn partner Rebecca Gilsenan and barristers David Catterns QC and Peter Cashman.

"There is a philosophical and ethical issue about the commercialisation of the human body. Beyond that, there is a practical concern - the patent owner has a right to prevent people from studying and testing for the gene mutation, so gene patents can stifle research, the development of treatments, and access to diagnostic testing," said Gilsenan.

"Patents protect inventions, not discoveries. What Myriad has done is discovered and isolated the gene from the human body. We will argue that that does not and can not amount to a patentable invention," said Gilsenan.

Cancer Voices, the first applicant in the case, has a strong interest in ensuring that all cancer patients receive access to the best available treatments.

The organisation’s executive officer, John Stubbs, said cancer victims want control over disease and treatment options.

“Patents have the potential to increase the cost of treating all cancers and perhaps denying a vital pathway to good treatment outcomes.”

Yvonne D'Arcy, the second applicant in the case, believes patents over human genes are morally wrong.

"It's just not right that a company can come along and say that it owns a gene and then control how you get tested for it and who can test you. A company shouldn't be able to own genes - they belong to everybody.”

Five to 10 per cent of women with breast cancer have a known gene mutation and many others have a strong family history. At least 20 per cent of human genes are patented and the outcome of this test case will have implications for status of other patents on other genetic material.

Like this story? Read more:

QLS condemns actions of disgraced lawyer as ‘stain on the profession’

NSW proposes big justice reforms to target risk of reoffending

The legal budget breakdown 2017


Firm prepares for cancer patents hearing
lawyersweekly logo
Promoted content
Recommended by Spike Native Network
more from lawyers weekly
LCA president Fiona McLeod SC
Aug 17 2017
Where social fault lines meet the justice gap in Aus
After just returning from a tour of the Northern Territory, LCA president Fiona McLeod SC speaks wit...
Marriage equality flag
Aug 17 2017
ALHR backs High Court challenge to marriage equality postal vote
Australian Lawyers for Human Rights (ALHR) has voiced its support for a constitutional challenge to ...
Give advice
Aug 17 2017
A-G issues advice on judiciary’s public presence
Commonwealth Attorney-General George Brandis QC has offered his advice on the public presence of jud...
APPOINTMENTS
Allens managing partner Richard Spurio, image courtesy Allens' website
Jun 21 2017
Promo season at Allens
A group of lawyers at Allens have received promotions across its PNG and Australian offices. ...
May 11 2017
Partner exits for in-house role
A Victorian lawyer has left the partnership of a national firm to start a new gig with state governm...
Esteban Gomez
May 11 2017
National firm recruits ‘major asset’
A national law firm has announced it has appointed a new corporate partner who brings over 15 years'...
opinion
Nicole Rich
May 16 2017
Access to justice for young transgender Australians
Reform is looming for the process that young transgender Australians and their families must current...
Geoff Roberson
May 11 2017
The lighter side of the law: when law and comedy collide
On the face of it, there doesn’t seem to be much that is amusing about the law, writes Geoff Rober...
Help
May 10 2017
Advocate’s immunity – without fear or without favour but not both
On 29 March 2017, the High Court handed down its decision in David Kendirjian v Eugene Lepore & ...